Navigation Links
Telik Announces New TRAP Drug Discovery Agreement
Date:11/12/2008

PALO ALTO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS studies the mechanisms underlying musculoskeletal and autoimmune diseases to discover effective treatments for these disorders. HSS investigators will use Telik's TRAP technology to discover novel compounds that inhibit a key enzyme in cell signaling and migration.

"By efficiently identifying novel small molecules that affect biological targets, Telik's TRAP technology offers a unique opportunity to accelerate our research," said Carl Blobel, M.D., Ph.D., Professor of Medicine, Physiology, and Biophysics, and Director of the Arthritis and Tissue Degeneration Program at HSS. "We are interested in membrane bound enzymes and the biological effects that result from their modulation. Rapidly finding small molecules that inhibit these enzymes could lead to new ways to treat diseases for which there is significant unmet medical need."

"This partnership allows the world-class investigators at HSS to leverage our recent advances in TRAP technology to accelerate the discovery of new therapeutics that target complex and novel biological targets," said Robert Lum, Ph.D., Telik's Vice President of Technology and Preclinical Development.

TRAP technology exploits the principle that drugs act by adhering to and interacting with cellular proteins. Telik has developed a novel computational approach to determine a molecular fingerprint for each of the over three million compounds in its library. TRAP technology uses these molecular fingerprints to rapidly search the library for promising lead molecules and to optimize these structures into new drug candidates.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

Forward Looking Statements

This press release contains "forward-looking" statements, including statements regarding the potential application and capabilities of TRAP, and the potential utility of TRAP to HSS' drug discovery efforts. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended September 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Financial Results for 2008 Third Quarter
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
4. Telik Announces Receipt of Nasdaq Notice
5. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
6. ReceptorBio Announces Diabetes License Agreement With Telik
7. Telik Announces Financial Results For 2008 Second Quarter
8. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
9. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
10. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
11. Telik Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... - BioAmber Inc. (NYSE: BIOA ), a leader ... & Co. Ltd., its partner in the ... an additional CDN$25 million in the joint venture for ... to 40%.  Mitsui will also play a stronger role ... Sarnia , providing dedicated resources alongside BioAmber,s ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House ... , has announced that University of Maryland School of ... MBA and University of Maryland Medical System President and ... the "Speaker,s Medallion," the highest honor given to the ... Delegates. Dean Reece and Mr. Chrencik ...
(Date:2/10/2016)... Feb. 10, 2016 NX Prenatal Inc., a ... NeXosome® technology for early warning of adverse pregnancy ... recent study by Dr. Thomas McElrath ... Maternal Fetal Medicine,s (SMFM) annual meeting held in ... , 2016.  The presentation reported initial positive top-line ...
Breaking Biology Technology:
(Date:2/10/2016)... February 10, 2016 ... to 2016 iris recognition market report, combined ... is more widely accepted for border control. ... fingerprint and iris recognition technology in a ... avoid purchasing two individual biometrics devices. ...
(Date:2/9/2016)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2015.  ... 2015 was $6.9 million, an increase of 61% compared to $4.3 ... fourth quarter of 2015 was $2.6 million compared to $0.2 million ... --> Higher revenue and operating income in the ...
(Date:2/9/2016)... 9, 2016 Vigilant Solutions announces today that an ... to develop a lead in a difficult homicide case. The ... to locate the suspect vehicle. Due to the ongoing investigation, ... been omitted at the agency,s request. --> ... "Our victim was found deceased at an intersection here in ...
Breaking Biology News(10 mins):